港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

派格生物醫藥-B

5.960

+0.0851.45%

成交量：537.80萬

成交額：3,192.75萬

市值：23.30億

市盈率：-10.84

高：6.110

開：5.925

低：5.750

收：5.875

52周最高：77.000

52周最低：4.940

股本：3.91億

香港流通股本：3.86億

量比：0.46

換手率：1.39%

股息：- -

股息率：- -

每股收益(LYR):-0.550

淨資產收益率：-82.42%

總資產收益率：-31.46%

市淨率：4.46

市盈率(LYR):-10.84

市銷率: -515.93

資料載入中...

總覽公司新聞資訊公告

派格生物醫藥-B（02565）擬於8月25日召開董事會審議2026年中期業績

異動解讀｜派格生物醫藥-B盤中上漲8.82%，派達康商業化持續催化估值修復

港股異動 | 派格生物醫藥-B(02565.HK)尾盤放量升逾36% 派達康全國首批處方落地第二筆權益金付款條件同步達成

異動解讀｜派格生物醫藥-B盤中上漲8.93%，派達康全國首批商業化處方落地觸發里程碑付款

派格生物醫藥－Ｂ(02565)股價上升5.075%，現價港幣$5.59

阿斯达克财经

派格生物醫藥-B更新7月股份變動月報表，股本保持不變

異動解讀｜派格生物醫藥-B盤中下跌8.64%，報5.39港元

派格生物醫藥－Ｂ(02565)股價下跌5.085%，現價港幣$5.6

阿斯达克财经

異動解讀｜派格生物醫藥-B盤中下跌8.36%，報5.81港元

異動解讀｜派格生物醫藥-B盤中下跌8.12%，報6.34港元

港股異動 | 派格生物醫藥-B(02565.HK)升逾6% 派達康全國首批商業化處方落地獲第二筆權益金約4900萬港元

首批處方落地即觸發4900萬港元權益金派格生物(02565.HK)商業化進入價值兑現期

派格生物醫藥-B(02565)：派達康®全國首批商業化處方落地及第二筆權益金付款條件達成

派格生物醫藥-B(02565)派達康®落地全國首批商業化處方觸發4,900萬港元里程碑付款

異動解讀｜派格生物醫藥-B盤中上漲8.04%，三方戰略合作加速派達康商業化放量預期

港股異動 | 派格生物醫藥-B(02565)升逾5% 攜手三方共同加速打通派達康商業化鏈路產品市場放量蓄勢待發

阿里健康宣佈與天力士製藥、派格生物醫藥就GLP-1RA藥物達成戰略合作

派格生物-B(02565)聯手騰瑞製藥、阿里健康，派達康商業化鏈路加速打通，市場放量蓄勢待發

異動解讀｜派格生物醫藥-B盤中下跌8.04%，Rani合作催化消退疊加生物科技板塊集體走弱

異動解讀｜派格生物醫藥-B盤中上漲8.78%，Rani合作催化疊加前日回調後技術性反彈

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/02565/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02565","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02565\",,,,,undefined,":{"symbol":"02565","market":"HK","secType":"STK","nameCN":"派格生物醫藥-B","latestPrice":5.96,"timestamp":1787558901005,"preClose":5.875,"halted":0,"volume":5377950,"delay":0,"changeRate":0.014468085106382972,"floatShares":386000000,"shares":391000000,"eps":-0.55,"marketStatus":"已收盤","change":0.085,"latestTime":"08-24 16:08:21","open":5.925,"high":6.11,"low":5.75,"amount":31927471,"amplitude":0.061277,"askPrice":5.965,"askSize":12200,"bidPrice":5.96,"bidSize":1250,"shortable":3,"etf":0,"ttmEps":-0.612785,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1787621400000},"marketStatusCode":5,"adr":0,"listingDate":1748275200000,"exchange":"SEHK","adjPreClose":5.875,"openAndCloseTimeList":[[1787535000000,1787544000000],[1787547600000,1787558400000]],"volumeRatio":0.462276,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02565\",,,,,undefined,":{"symbol":"02565","floatShares":386000000,"roa":"-31.46%","roe":"-82.42%","lyrEps":-0.55,"volumeRatio":0.462276,"shares":391000000,"dividePrice":0,"high":6.11,"amplitude":0.061277,"preClose":5.875,"low":5.75,"week52Low":4.94,"pbRate":"4.46","psRate":"-515.93","week52High":77,"institutionHeld":0,"latestPrice":5.96,"committee":-0.814126,"eps":-0.55,"divideRate":0,"volume":5377950,"delay":0,"ttmEps":-0.612785,"open":5.925,"prevYearClose":69,"prevWeekClose":5.875,"prevMonthClose":5.36,"prevQuarterClose":5.33,"fiveDayClose":6.18,"twentyDayClose":6.34,"sixtyDayClose":8.83,"earningDate":1787587200000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02565\",params:#limit:5,,,undefined,":[{"date":"2026-08-25","symbol":"02565","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787621400000,"name":null,"time":"","dateTimestamp":1787587200000,"actualEps":null},{"market":"HK","date":"2026-03-23","symbol":"02565","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1774195200000,"reportTimeType":"post","actualEps":null},{"date":"2025-08-26","symbol":"02565","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756171800000,"name":null,"time":"","dateTimestamp":1756137600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02565\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02565\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02565\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02565","date":"2026-08-21","current":-9.726087,"percent":0.935811,"low":-87.782868,"twenty":-72.846173,"median":-58.454271,"eighty":-11.546541,"high":-7.824338,"avg":-44.305288,"sd":28.056716,"marketCap":2297662750},"quantilePoints":[{"date":"2025-05-30","current":-12.743079,"twenty":-15.470266,"median":-13.542645,"eighty":-13.135794,"marketCap":3936746426},{"date":"2025-06-06","current":-11.987888,"twenty":-13.726785,"median":-12.740515,"eighty":-12.114178,"marketCap":3712892217},{"date":"2025-06-13","current":-11.23576,"twenty":-13.295707,"median":-12.114337,"eighty":-11.528404,"marketCap":3481318898},{"date":"2025-06-20","current":-11.30775,"twenty":-12.841258,"median":-11.963331,"eighty":-11.337793,"marketCap":3496757119},{"date":"2025-06-27","current":-12.421214,"twenty":-12.738977,"median":-11.541778,"eighty":-11.292079,"marketCap":3851836209},{"date":"2025-07-04","current":-13.963875,"twenty":-12.971799,"median":-11.987888,"eighty":-11.299391,"marketCap":4330421069},{"date":"2025-07-11","current":-13.604213,"twenty":-13.050401,"median":-12.199189,"eighty":-11.305737,"marketCap":4214634409},{"date":"2025-07-18","current":-16.956264,"twenty":-13.748078,"median":-12.438987,"eighty":-11.330282,"marketCap":5248995235},{"date":"2025-07-25","current":-19.006677,"twenty":-15.472199,"median":-12.742066,"eighty":-11.352726,"marketCap":5905119639},{"date":"2025-08-01","current":-19.199848,"twenty":-18.276271,"median":-12.906561,"eighty":-11.424474,"marketCap":5928276971},{"date":"2025-08-08","current":-20.51103,"twenty":-19.019895,"median":-13.05938,"eighty":-11.472546,"marketCap":6348968501},{"date":"2025-08-15","current":-39.959751,"twenty":-19.179784,"median":-13.542645,"eighty":-11.515029,"marketCap":12350577024},{"date":"2025-08-22","current":-41.864246,"twenty":-19.284777,"median":-13.964282,"eighty":-11.779976,"marketCap":12898633879},{"date":"2025-08-29","current":-41.44792,"twenty":-21.432837,"median":-14.946806,"eighty":-11.968242,"marketCap":10033166343},{"date":"2025-09-05","current":-50.678037,"twenty":-39.039264,"median":-17.018603,"eighty":-12.06328,"marketCap":12255314482},{"date":"2025-09-12","current":-58.538001,"twenty":-40.749762,"median":-18.438762,"eighty":-12.114019,"marketCap":14181548421},{"date":"2025-09-19","current":-57.311117,"twenty":-43.720929,"median":-18.952908,"eighty":-12.216159,"marketCap":13874467648},{"date":"2025-09-26","current":-63.587749,"twenty":-49.33228,"median":-19.070122,"eighty":-12.366345,"marketCap":15354038645},{"date":"2025-10-03","current":-60.149194,"twenty":-54.575673,"median":-19.16943,"eighty":-12.428323,"marketCap":14558420278},{"date":"2025-10-10","current":-60.121463,"twenty":-57.957283,"median":-19.199848,"eighty":-12.49878,"marketCap":14530503844},{"date":"2025-10-17","current":-60.168303,"twenty":-59.756564,"median":-19.2984,"eighty":-12.738571,"marketCap":14530503844},{"date":"2025-10-24","current":-61.301982,"twenty":-60.143648,"median":-20.51103,"eighty":-12.741458,"marketCap":14809668183},{"date":"2025-10-31","current":-69.345185,"twenty":-60.159469,"median":-22.018639,"eighty":-12.743079,"marketCap":16777776773},{"date":"2025-11-07","current":-59.401661,"twenty":-60.392128,"median":-34.33922,"eighty":-12.780248,"marketCap":14363005241},{"date":"2025-11-14","current":-72.819022,"twenty":-61.035505,"median":-39.959751,"eighty":-12.906561,"marketCap":17657144441},{"date":"2025-11-21","current":-72.852961,"twenty":-61.301982,"median":-40.866122,"eighty":-12.943343,"marketCap":17657144441},{"date":"2025-11-28","current":-82.344376,"twenty":-62.346137,"median":-42.423494,"eighty":-13.014482,"marketCap":20030041323},{"date":"2025-12-05","current":-72.063717,"twenty":-63.355663,"median":-45.122001,"eighty":-13.104279,"marketCap":17559436923},{"date":"2025-12-12","current":-74.217813,"twenty":-64.460997,"median":-48.969529,"eighty":-13.233973,"marketCap":18117765601},{"date":"2025-12-19","current":-71.875632,"twenty":-65.413889,"median":-52.055133,"eighty":-13.542645,"marketCap":17587353357},{"date":"2025-12-24","current":-73.927127,"twenty":-69.382811,"median":-55.337969,"eighty":-13.579586,"marketCap":18145682035},{"date":"2026-01-02","current":-79.895405,"twenty":-70.540926,"median":-57.311117,"eighty":-13.748078,"marketCap":19687798475},{"date":"2026-01-09","current":-85.854057,"twenty":-72.056904,"median":-58.941314,"eighty":-13.964201,"marketCap":21208805289},{"date":"2026-01-16","current":-80.413876,"twenty":-72.839385,"median":-59.401661,"eighty":-14.164153,"marketCap":19929453763},{"date":"2026-01-23","current":-77.735339,"twenty":-73.262106,"median":-59.808211,"eighty":-14.656731,"marketCap":19247132950},{"date":"2026-01-30","current":-73.838267,"twenty":-73.550435,"median":-60.0941,"eighty":-15.472199,"marketCap":18365801899},{"date":"2026-02-06","current":-69.490034,"twenty":-73.32273,"median":-60.154331,"eighty":-16.538679,"marketCap":17328105662},{"date":"2026-02-13","current":-71.473742,"twenty":-73.562339,"median":-60.192909,"eighty":-17.006135,"marketCap":17925136373},{"date":"2026-02-20","current":-71.065981,"twenty":-73.716985,"median":-60.392128,"eighty":-17.056006,"marketCap":17797201221},{"date":"2026-02-27","current":-72.540901,"twenty":-73.438012,"median":-60.796223,"eighty":-17.950543,"marketCap":18365801899},{"date":"2026-03-06","current":-68.036226,"twenty":-73.352041,"median":-61.160082,"eighty":-18.384598,"marketCap":17086450373},{"date":"2026-03-13","current":-60.794114,"twenty":-73.299371,"median":-60.919795,"eighty":-18.597951,"marketCap":15338003289},{"date":"2026-03-20","current":-67.303035,"twenty":-73.275932,"median":-61.206433,"eighty":-18.84686,"marketCap":16915870170},{"date":"2026-03-27","current":-68.867925,"twenty":-73.269478,"median":-61.274827,"eighty":-18.985169,"marketCap":16247764373},{"date":"2026-04-02","current":-85.055535,"twenty":-73.278872,"median":-61.433108,"eighty":-19.026504,"marketCap":20163286400},{"date":"2026-04-10","current":-78.454069,"twenty":-73.369897,"median":-61.662876,"eighty":-19.045802,"marketCap":18741784705},{"date":"2026-04-17","current":-76.94604,"twenty":-73.948705,"median":-62.45145,"eighty":-19.079188,"marketCap":18389252284},{"date":"2026-04-24","current":-60.4786,"twenty":-73.948705,"median":-62.528681,"eighty":-19.126247,"marketCap":14454535592},{"date":"2026-05-15","current":-17.642518,"twenty":-73.927127,"median":-62.346137,"eighty":-19.115451,"marketCap":4376314243},{"date":"2026-05-22","current":-20.448357,"twenty":-73.838267,"median":-61.433108,"eighty":-19.16943,"marketCap":5060724424},{"date":"2026-05-29","current":-13.590249,"twenty":-73.716985,"median":-61.274827,"eighty":-19.064042,"marketCap":3375119921},{"date":"2026-06-05","current":-12.579887,"twenty":-73.438012,"median":-61.206433,"eighty":-18.597951,"marketCap":3128732256},{"date":"2026-06-12","current":-11.565594,"twenty":-73.352041,"median":-60.919795,"eighty":-17.056006,"marketCap":2874522760},{"date":"2026-06-18","current":-9.622776,"twenty":-73.31105,"median":-60.791238,"eighty":-14.753422,"marketCap":2397391091},{"date":"2026-06-26","current":-7.824338,"twenty":-73.278872,"median":-60.512398,"eighty":-13.899973,"marketCap":1939813998},{"date":"2026-07-03","current":-8.984958,"twenty":-73.271235,"median":-60.431019,"eighty":-13.561687,"marketCap":2229221732},{"date":"2026-07-10","current":-11.252888,"twenty":-73.25947,"median":-60.210807,"eighty":-13.050401,"marketCap":2788482623},{"date":"2026-07-17","current":-10.458113,"twenty":-73.235067,"median":-60.159469,"eighty":-12.830773,"marketCap":2600758687},{"date":"2026-07-24","current":-10.046967,"twenty":-73.215248,"median":-60.107782,"eighty":-12.739192,"marketCap":2499074889},{"date":"2026-07-31","current":-8.411523,"twenty":-73.183292,"median":-59.862622,"eighty":-12.522041,"marketCap":2096250611},{"date":"2026-08-07","current":-10.298244,"twenty":-73.061453,"median":-59.675079,"eighty":-12.306772,"marketCap":2571426822},{"date":"2026-08-14","current":-9.745542,"twenty":-72.966779,"median":-59.367669,"eighty":-11.991332,"marketCap":2436500244},{"date":"2026-08-21","current":-9.169953,"twenty":-72.846173,"median":-58.454271,"eighty":-11.546541,"marketCap":2297662750}],"updateTime":1787576920202},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02565\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1184545548","title":"派格生物醫藥-B（02565）擬於8月25日召開董事會審議2026年中期業績","url":"https://stock-news.laohu8.com/highlight/detail?id=1184545548","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184545548?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 17:01","pubTimestamp":1786611710,"startTime":"0","endTime":"0","summary":"派格生物医药（杭州）股份有限公司（02565）8月13日公告，公司董事会将于2026年8月25日（星期二）召开会议，主要议程包括：\n1. 审议及批准本集团截至2026年6月30日止六个月的中期业绩及其刊发；  \n2. 处理任何其他事项。\n董事长、执行董事兼总经理Michael Min Xu将在会上主持相关事宜。除其本人外，董事会成员还包括执行董事王小军，非执行董事Xiangjun Zhou、徐宇虹、翟婷、李宏凯，以及独立非执行董事Jiancun Zhang、陈秧秧、廖亦琳。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156396796","title":"異動解讀｜派格生物醫藥-B盤中上漲8.82%，派達康商業化持續催化估值修復","url":"https://stock-news.laohu8.com/highlight/detail?id=1156396796","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156396796?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 10:54","pubTimestamp":1786589641,"startTime":"0","endTime":"0","summary":"8月13日，派格生物医药-B盘中上涨8.82%，报6.725港元，成交额8605.05万港元。消息面上，公司核心产品派达康近期在全国多家医疗机构及线上渠道开出首批商业化处方，触发第二笔约4900万港元里程碑付款，连同此前已收取的6100万港元，累计已收及触发权益金约1.1亿港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657154826","title":"港股異動 | 派格生物醫藥-B(02565.HK)尾盤放量升逾36% 派達康全國首批處方落地 第二筆權益金付款條件同步達成","url":"https://stock-news.laohu8.com/highlight/detail?id=2657154826","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657154826?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 16:24","pubTimestamp":1786091061,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175037803","title":"異動解讀｜派格生物醫藥-B盤中上漲8.93%，派達康全國首批商業化處方落地觸發里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1175037803","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175037803?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 14:52","pubTimestamp":1786085521,"startTime":"0","endTime":"0","summary":"8月7日，派格生物医药-B盘中上涨8.93%，报5.805港元，成交额4175.36万港元。消息面上，公司核心产品派达康已在北京大学人民医院、中南大学湘雅二医院等多家医疗机构开出全国首批商业化处方，腾瑞制药已确认将支付约4900万港元第二笔权益金。此前公司已收到首笔权益金6100万港元，商业化里程碑付款持续兑现。此外，公司已与腾瑞制药、阿里健康签署三方战略合作协议，加速打通线上线下商业化链路，产品放量蓄势待发。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657150697","title":"派格生物醫藥－Ｂ(02565)股價上升5.075%，現價港幣$5.59","url":"https://stock-news.laohu8.com/highlight/detail?id=2657150697","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657150697?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 14:45","pubTimestamp":1786085100,"startTime":"0","endTime":"0","summary":"[上升股]派格生物医药－Ｂ(02565) 股价在下午02:45比前收市价上升5.075%，现股价为港币$5.59。至目前为止，今日最高价为$5.59，而最低价为$5.315。总成交量为499.75万股，总成交金额为港币$2.717千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2608072329/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2608072329/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["399441","BK1161","02565","161726"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198617267","title":"派格生物醫藥-B更新7月股份變動月報表，股本保持不變","url":"https://stock-news.laohu8.com/highlight/detail?id=1198617267","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198617267?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 17:13","pubTimestamp":1785921210,"startTime":"0","endTime":"0","summary":"派格生物医药(杭州)股份有限公司于2026年8月5日公告了截至2026年7月31日的股份变动月报表。公告显示，本月公司已发行股份及注册股本均未发生新增发行或减少，股本保持稳定。根据公告，公司主要股本结构包括H股和非上市股份。公司本月底注册股本总额记为人民币391,091,532元，相比上月底并无增减变动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187818353","title":"異動解讀｜派格生物醫藥-B盤中下跌8.64%，報5.39港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1187818353","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187818353?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 15:20","pubTimestamp":1785396008,"startTime":"0","endTime":"0","summary":"7月30日，派格生物医药-B盘中下跌8.64%，报5.39港元/股，成交额2731.27万港元。派格生物医药-B所在的生物科技行业中，个股中，信达生物跌1.73%，康方生物跌2.14%，百济神州跌1.31%，科伦博泰生物跌3.78%，三生制药跌1.03%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655444678","title":"派格生物醫藥－Ｂ(02565)股價下跌5.085%，現價港幣$5.6","url":"https://stock-news.laohu8.com/highlight/detail?id=2655444678","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655444678?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 11:55","pubTimestamp":1785383700,"startTime":"0","endTime":"0","summary":"[下跌股]派格生物医药－Ｂ(02565) 股价在上午11:55比前收市价下跌5.085%，现股价为港币$5.6。至目前为止，今日最高价为$5.99，而最低价为$5.6。总成交量为295.48万股，总成交金额为港币$1.71千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152745608_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152745608_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2607302129/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2607302129/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["399441","161726","02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118803082","title":"異動解讀｜派格生物醫藥-B盤中下跌8.36%，報5.81港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1118803082","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118803082?lang=zh_tw&edition=fundamental","pubTime":"2026-07-28 14:07","pubTimestamp":1785218875,"startTime":"0","endTime":"0","summary":"7月28日，派格生物医药-B盘中下跌8.36%，报5.81港元/股，成交额3469.47万港元。派格生物医药-B所在的生物科技行业中，个股中，维立志博-B跌6.89%，信达生物涨0.11%，百济神州跌2.8%，康诺亚-B跌5.29%，康方生物跌3.4%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177397709","title":"異動解讀｜派格生物醫藥-B盤中下跌8.12%，報6.34港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1177397709","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177397709?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 14:00","pubTimestamp":1784872801,"startTime":"0","endTime":"0","summary":"7月24日，派格生物医药-B盘中下跌8.12%，报6.34港元/股，成交额4470.26万港元。派格生物医药-B所在的生物科技行业中，个股中，信达生物跌1.48%，百济神州涨2.48%，康方生物跌3.89%，科伦博泰生物跌1.34%，三生制药跌2.16%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653879706","title":"港股異動 | 派格生物醫藥-B(02565.HK)升逾6% 派達康全國首批商業化處方落地 獲第二筆權益金約4900萬港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653879706","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653879706?lang=zh_tw&edition=fundamental","pubTime":"2026-07-23 09:33","pubTimestamp":1784770436,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653775152","title":"首批處方落地即觸發4900萬港元權益金 派格生物(02565.HK)商業化進入價值兑現期","url":"https://stock-news.laohu8.com/highlight/detail?id=2653775152","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653775152?lang=zh_tw&edition=fundamental","pubTime":"2026-07-22 18:30","pubTimestamp":1784716234,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653647759","title":"派格生物醫藥-B(02565)：派達康®全國首批商業化處方落地及第二筆權益金付款條件達成","url":"https://stock-news.laohu8.com/highlight/detail?id=2653647759","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653647759?lang=zh_tw&edition=fundamental","pubTime":"2026-07-22 18:08","pubTimestamp":1784714890,"startTime":"0","endTime":"0","summary":"根据本集团与腾瑞制药订立的商业化合作协议，随着派达康全国首批商业化处方顺利开出，协议约定的第二笔权益金付款条件已全部达成，腾瑞制药支付该笔权益金的义务已正式生效。董事会认为，派达康全国首批商业化处方的落地，是该产品正式进入临床应用及患者服务阶段的重要里程碑;第二笔权益金付款条件的达成，亦进一步体现本集团与腾瑞制药商业化合作的实质推进及持续履约。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470969.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4581","BK4585","399441","161726","XBI","BK4588","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152538651","title":"派格生物醫藥-B(02565)派達康®落地全國首批商業化處方 觸發4,900萬港元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1152538651","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152538651?lang=zh_tw&edition=fundamental","pubTime":"2026-07-22 18:05","pubTimestamp":1784714748,"startTime":"0","endTime":"0","summary":"2026年7月22日，派格生物医药-B发布自愿性公告称，其自主研发的长效GLP-1受体激动剂维培那肽注射液已在北京大学人民医院、中南大学湘雅二医院等多家医疗机构开出全国首批商业化处方。腾瑞制药已书面确认，将支付约港币4,900万元的第二笔权益金，派格生物医药-B预计在协议约定期限内收取该款项。加上即将到账的4,900万元，派达康在商业化合作层面的里程碑付款持续推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132079551","title":"異動解讀｜派格生物醫藥-B盤中上漲8.04%，三方戰略合作加速派達康商業化放量預期","url":"https://stock-news.laohu8.com/highlight/detail?id=1132079551","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132079551?lang=zh_tw&edition=fundamental","pubTime":"2026-07-21 14:58","pubTimestamp":1784617128,"startTime":"0","endTime":"0","summary":"7月21日，派格生物医药-B盘中上涨8.04%，报7.39港元，成交额1.47亿港元。消息面上，7月17日，派格生物医药-B与上海腾瑞制药及阿里健康在杭州正式签署战略合作协议，三方将整合医药研发、生产及数字化健康服务资源，共同推进核心产品派达康的商业化进程。派达康已获批用于成人2型糖尿病治疗，属独家品种，并已通过国家医保目录调整初步形式审查。市场关注重点已由产品获批转向医院覆盖及线上线下协同带来的放量速度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652235261","title":"港股異動 | 派格生物醫藥-B(02565)升逾5% 攜手三方共同加速打通派達康商業化鏈路 產品市場放量蓄勢待發","url":"https://stock-news.laohu8.com/highlight/detail?id=2652235261","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652235261?lang=zh_tw&edition=fundamental","pubTime":"2026-07-20 11:43","pubTimestamp":1784519009,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，派格生物医药-B涨超5%，截至发稿，涨5.41%，报7.01港元，报1.32亿港元。消息面上，7月17日，派格生物医药-B、上海腾瑞制药股份有限公司与阿里健康在杭州正式签署战略合作协议。下一阶段，市场对派达康的关注重点，将由“产品能否获批”转向医院覆盖、医生处方、患者持续用药以及线上线下协同带来的放量速度。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469612.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4581","399441","KCAI","XBI","VXUS","161726","02565","BK4588","BK4585","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196884965","title":"阿里健康宣佈與天力士製藥、派格生物醫藥就GLP-1RA藥物達成戰略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1196884965","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196884965?lang=zh_tw&edition=fundamental","pubTime":"2026-07-17 19:58","pubTimestamp":1784289496,"startTime":"0","endTime":"0","summary":"阿里健康发布公告称，已与天力士制药及派格生物医药-B正式签署关于GLP-1RA药物的战略合作协议。此举旨在整合各方在医药研发、生产及数字化健康服务领域的优势资源，共同推进该创新药物的开发与商业化进程。GLP-1RA类药物近年来在全球糖尿病及肥胖症治疗市场备受关注，市场潜力巨大。通过此次合作，阿里健康有望进一步强化其医药健康生态布局，而天力士制药与派格生物医药-B则将借助阿里健康的平台与用户基础，加速产品市场渗透。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00241","BK1589","BK1515","02565","BK1161","BK1247","BK1617","HK0000165453.HKD","BK1189","BK1501","BK1591","BK1142","BK1502","BK1584","BK1571","BK1615","BK1610"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652404980","title":"派格生物-B(02565)聯手騰瑞製藥、阿里健康，派達康商業化鏈路加速打通，市場放量蓄勢待發","url":"https://stock-news.laohu8.com/highlight/detail?id=2652404980","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652404980?lang=zh_tw&edition=fundamental","pubTime":"2026-07-17 18:00","pubTimestamp":1784282400,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月17日，派格生物-B、上海腾瑞制药股份有限公司与阿里健康在杭州正式签署战略合作协议。派达康已获批用于成人2型糖尿病治疗。对于派格生物而言，此次与腾瑞制药、阿里健康达成战略合作，不仅进一步完善了派达康的商业化版图，也释放出更加清晰的信号：随着产品差异化、全国推广网络和数字化患者入口逐步汇合，派达康正由商业化准备阶段加速驶入真实市场验证阶段，后续放量已蓄势待发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1142","BK1502","02565","HK0000165453.HKD","BK1617","BK1591","BK1189","BK1515","00241","BK1161","BK1247","BK1191","BK1589","BK1571","BK1574","BK1615","BK1584","BK1610","BK1501","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142608450","title":"異動解讀｜派格生物醫藥-B盤中下跌8.04%，Rani合作催化消退疊加生物科技板塊集體走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1142608450","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142608450?lang=zh_tw&edition=fundamental","pubTime":"2026-07-17 10:16","pubTimestamp":1784254603,"startTime":"0","endTime":"0","summary":"7月17日，派格生物医药-B盘中下跌8.04%，报6.2港元，成交额4767.38万港元。公司此前因与纳斯达克上市公司Rani Therapeutics签署谅解备忘录，股价于7月10日大涨约29%后持续波动，本次下跌系前期催化效应消退后获利盘持续兑现。同日生物科技板块整体承压，康方生物跌9.68%，三生制药跌9.21%，科伦博泰生物跌4.38%，信达生物跌3.77%，百济神州跌2.73%，板块联动效应加剧个股抛压。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142511876","title":"異動解讀｜派格生物醫藥-B盤中上漲8.78%，Rani合作催化疊加前日回調後技術性反彈","url":"https://stock-news.laohu8.com/highlight/detail?id=1142511876","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142511876?lang=zh_tw&edition=fundamental","pubTime":"2026-07-15 09:46","pubTimestamp":1784079975,"startTime":"0","endTime":"0","summary":"7月15日，派格生物医药-B盘中上涨8.78%，报6.82港元，成交额7200.29万港元。公司此前因与纳斯达克上市公司Rani Therapeutics签署谅解备忘录，股价于7月10日大涨约29%，7月13日续涨逾4%后，7月14日因获利盘集中兑现回调约8%，本次上涨系短期超跌后的技术性修复。该谅解备忘录有效期三年，双方将依托Rani专有的RaniPill口服生物药递送平台，围绕派格生物多项肥胖症及代谢疾病候选资产开展口服制剂筛选及临床前开发，并探索中国以外市场的商业化合作。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":123,"code":"91000000","status":"200"}]}}